• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

问题与更新：乳腺癌中雌激素受体-α、孕激素受体和 HER2 的评估。

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

机构信息

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.

出版信息

Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55.

DOI:10.1038/modpathol.2010.55
PMID:20436503
Abstract

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.

摘要

目前有三种预后/预测生物标志物用于乳腺癌患者的常规临床管理，其评估是强制性的。它们包括雌激素受体-α（ERalpha）、孕激素受体（PgR）和 HER2 癌基因/癌蛋白。本文简要回顾了乳腺癌中 ERalpha、PgR 和 HER2 的评估，强调了最近的进展和持续存在的争议。

相似文献

1
Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.问题与更新：乳腺癌中雌激素受体-α、孕激素受体和 HER2 的评估。
Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55.
2
Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.雌激素受体-β在浸润性乳腺癌中与分子表型的关系：来自护士健康研究的结果。
Mod Pathol. 2010 Feb;23(2):197-204. doi: 10.1038/modpathol.2009.158. Epub 2009 Nov 6.
3
Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.转移至脑部的人类乳腺癌中受体表达的异质性。
Tumour Biol. 2014 Jul;35(7):7267-73. doi: 10.1007/s13277-014-1979-9. Epub 2014 Apr 29.
4
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.高Ki-67表达和低孕激素受体表达可独立导致雌激素受体阳性且人表皮生长因子受体2阴性的绝经后乳腺癌患者预后较差。
Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.
5
Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.免疫组织化学与 RT-qPCR 检测评估乳腺癌患者 ER、PR、HER2 和 Ki67 及亚型的比较。
Breast Cancer Res Treat. 2022 Aug;194(3):517-529. doi: 10.1007/s10549-022-06649-6. Epub 2022 Jul 5.
6
Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.鉴定癌胚抗原相关细胞粘附分子（CGA）为乳腺癌中一种新的雌激素受体反应性基因：预测内分泌治疗反应的杰出候选标志物。
Cancer Res. 2001 Feb 15;61(4):1652-8.
7
Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.基于雌激素和孕激素受体表达比率的乳腺癌样本风险分层改进
Anticancer Res. 2016 Aug;36(8):3855-63.
8
ERα-36 regulates progesterone receptor activity in breast cancer.雌激素受体 α-36 调节乳腺癌中孕激素受体的活性。
Breast Cancer Res. 2020 May 19;22(1):50. doi: 10.1186/s13058-020-01278-7.
9
Some DCIS is different molecularly from DCIS with co-existing IDC.一些导管原位癌在分子层面上与同时存在浸润性导管癌的导管原位癌不同。
Breast J. 2008 Jan-Feb;14(1):122-3. doi: 10.1111/j.1524-4741.2007.00536.x.
10
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.乳腺癌中的雄激素受体：在雌激素受体阳性肿瘤和具有大汗腺分化的雌激素受体阴性肿瘤中的表达。
Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.

引用本文的文献

1
HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer.HER2相互作用组分析揭示MARCKS是与侵袭性乳腺癌相关的候选标志物。
Cancers (Basel). 2025 Sep 2;17(17):2882. doi: 10.3390/cancers17172882.
2
The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.乳腺癌生物标志物在诊断、预后及治疗监测中的评估：综合分析
J Cancer Res Clin Oncol. 2025 Aug 22;151(8):233. doi: 10.1007/s00432-025-06271-1.
3
Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
评估术前中性粒细胞与淋巴细胞比值作为原发性乳腺癌患者临床病理参数预测指标的临床效用。
Breast Cancer Res Treat. 2025 Apr;210(3):783-790. doi: 10.1007/s10549-025-07615-8. Epub 2025 Jan 20.
4
The Impact of the Coexpression of and Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset.和基因共表达对乳腺癌预后指标及临床结局的影响：METABRIC数据集分析
Breast J. 2024 May 9;2024:2582341. doi: 10.1155/2024/2582341. eCollection 2024.
5
Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.开发一个列线图模型，用于预测日本乳腺癌患者使用 Oncotype DX 获得的复发评分。
Breast Cancer. 2024 Nov;31(6):1018-1027. doi: 10.1007/s12282-024-01616-z. Epub 2024 Jul 17.
6
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.乳腺癌 2024 年的生物标志物：西班牙肿瘤内科学会和西班牙病理学会的最新共识声明。
Clin Transl Oncol. 2024 Dec;26(12):2935-2951. doi: 10.1007/s12094-024-03541-1. Epub 2024 Jun 13.
7
Roles of Mesenchymal Stem Cells in Breast Cancer Therapy: Engineered Stem Cells and Exosomal Cell-Free Based Therapy.间充质干细胞在乳腺癌治疗中的作用：工程化干细胞与基于外泌体的无细胞疗法
Curr Mol Med. 2025;25(4):431-444. doi: 10.2174/0115665240274818231207054037.
8
Androgen Receptor Expression in ER and PR Negative Breast Cancer-A Study from a Tertiary Hospital in Northern India.雄激素受体在雌激素受体和孕激素受体阴性乳腺癌中的表达——来自印度北部一家三级医院的研究
South Asian J Cancer. 2023 May 29;12(4):319-325. doi: 10.1055/s-0043-1768920. eCollection 2023 Oct.
9
MAF1 is a predictive biomarker in HER2 positive breast cancer.MAF1 是 HER2 阳性乳腺癌的预测性生物标志物。
PLoS One. 2023 Oct 6;18(10):e0291549. doi: 10.1371/journal.pone.0291549. eCollection 2023.
10
Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer.循环 microRNAs 可预测原发性乳腺癌患者化疗引起的毒性。
Breast Cancer Res Treat. 2023 Nov;202(1):73-81. doi: 10.1007/s10549-023-07033-8. Epub 2023 Aug 4.